1 / 7

Acute Lymphocytic / Lymphoblastic Leukemia Market

The acute lymphoblastic leukemia therapeutics market is segmented based on the existing regimens and drugs, pipeline drugs, and geography. The existing regimes and drugs market currently includes three regimens (Hyper-CVAD, Linker, and CALGB 8811) and three monotherapy drugs (Oncaspar, Clolar, and Arranon). In addition, three drugs, namely, Graspa (ERYtech Pharma), Marqibo (Talon Therapeutics), and Inotuzumab Ozogamicin (Pfizer, Inc.) are in the pipeline (Phase III clinical trials).

sagmnm
Télécharger la présentation

Acute Lymphocytic / Lymphoblastic Leukemia Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MarketsandMarkets Presents Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html

  2. The acute lymphoblastic leukemia therapeutics market is segmented based on the existing regimens and drugs, pipeline drugs, and geography. The existing regimes and drugs market currently includes three regimens (Hyper-CVAD, Linker, and CALGB 8811) and three monotherapy drugs (Oncaspar, Clolar, and Arranon). In addition, three drugs, namely, Graspa (ERYtech Pharma), Marqibo (Talon Therapeutics), and Inotuzumab Ozogamicin (Pfizer, Inc.) are in the pipeline (Phase III clinical trials). The acute market is valued at an estimated $2,777.2 million in 2013 and is expected to reach $3,780.3 million by 2020, at a CAGR of 4.0% from 2015 to 2020. Browse >> http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html

  3. Acute Lymphocytic/Lymphoblastic Leukemia Market in G8 Countries, By Existing Regimen/Drugs ($Million) Source: MarketsandMarkets Analysis http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html

  4. Presently, the market is driven by factors such as the increasing incidence rate of ALL cases, development of innovative therapies such as multi-drug regimens, and continuous efforts of pharmaceutical companies to offer superior-quality drugs. Such improved regimens and drugs have shown significant results in the overall survival rate. The overall growth of the acute lymphocytic leukemia therapeutics market is largely challenged by the patent expiration of existing drugs. Arranon (nelarabine), a monotherapy drug, lost its patent in February 2013, whereas, Clolar (clofarabine) is due for patent expiration in 2018. Some of the major players in this market include ERYtech Pharma (France), Talon Therapeutic, Inc. (U.S.), GlaxoSmithKline plc (U.K.), Sigma-Tau Pharmaceuticals, Inc. (U.S.), Pfizer, Inc. (U.S.), and Genzyme Corporation (U.S.). . http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html

  5. The market primarily covers regimens and drugs (patented, off-patent, and pipeline). The growing acute lymphocytic leukemia population is an impetus for the growth of the market. This market is expected to grow at a CAGR of 4.0% from 2015 to 2020. In 2012, the overall ALL therapeutics market was dominated by Linker regimen, Hyper-CVAD regimen, and Nucleoside metabolic inhibitors treatments. However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.). In contrast to the growth of the market, the cost of the therapies is majorly restraining the acute lymphocytic leukemia therapeutics market. In addition, patent expirations of some of the existing drugs in the market are also expected to limit the market growth during 2013 to 2020. http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html

  6. Contact Us Mr. RohanNorth - Dominion Plaza, 17304 Preston Road, Suite 800, Dallas, TX 75252Tel: +1-888-6006-441Email: sales@marketsandmarkets.comMarketsandMarkets Bloghttp://twitter.com/marketsmarkets http://www.linkedin.com/company/marketsandmarkets http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html

  7. About MarketsandMarkets MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. They cover thirteen industry verticals, including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html

More Related